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osting by EAbstract Objective: Several nonsteroidal anti-inﬂammatory drugs (NSAIDs) have been linked to
cardiac death. The mechanism that is responsible for this adverse effect appears to be ischemic
insult; however, another possible mechanism involves hyperkalemia. The objective of the present
study was to determine the feasibility of conducting pharmacoepidemiological studies in Saudi
Arabia using reﬁll prescription data to investigate the association between NSAIDs and increased
serum potassium concentrations.
Methods: This retrospective cohort study included patients from an academic medical center in
Riyadh, Saudi Arabia. The patients who were recently prescribed NSAIDs were compared to a con-
trol group of paracetamol users, with respect to the drugs’ effects on serum potassium concentra-
tions. The covariates that affected the potassium concentration or the use of NSAIDs were
controlled for in the analysis. The studied outcome was the ﬁrst serum potassium concentration
of more than 5 mEq/L.
Results: A total of 184 patients were prescribed NSAIDs (n= 101) or paracetamol (n= 83) and
met the inclusion criteria. Compared to the control group, the patients who received NSAIDs were
more likely to be women, were less likely to use angiotensin-converting enzyme inhibitors, and were
more likely to have lower baseline serum creatinine concentrations. The other baseline characteristics
were similar between the patients in the NSAID group and the patients who received paracetamol.
Compared to the patients who were prescribed paracetamol, those who were prescribed NSAIDs didy. Production and hosting by
Saud University.
lsevier
70 H. Aljadheynot have an increased risk of hyperkalemia (odds ratio, 1.1, 95% conﬁdence interval, 0.17–6.7,
P= 0.95).
Conclusion: In the present, small feasibility study, no increase in the risk of hyperkalemia was
associated with NSAIDs compared to paracetamol. The present study was exploratory and included
only a small number of patients; therefore, this study may not be sufﬁciently powered to detect small
differences between the groups. Future studies with larger sample sizes are needed to investigate the
association between NSAIDs and hyperkalemia.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are widely
used to treat chronic conditions, including rheumatoid arthri-
tis and osteoarthritis. Selective cyclooxygenase-2 (COX-2)
inhibitors and non-selective NSAIDs are associated with ad-
verse cardiovascular events, such as myocardial infarction,
stroke, and sudden cardiac death (Graham et al., 2005; Bresa-
lier et al., 2005). The mechanisms that are responsible for these
cardiovascular events may include hyperkalemia. Hyperkale-
mia in patients with renal insufﬁciency or cardiovascular dis-
ease could lead to electrocardiographic abnormalities,
arrhythmia, and sudden cardiac death (Brater, 2002; Khanna
and White, 2009).
Hyperkalemia that results from NSAIDs has been re-
ported in several cases (Nielsen, 1999; Haragsim et al.,
1994; Patel et al., 2001; Hay et al., 2002; Braden et al.,
2004; Lam and Schneider, 2005; Kelley and Bastani, 1995).
In addition, NSAIDs have been shown to reduce the renal
excretion of potassium in acute interventional studies (Mur-
ray et al., 1997; Swan et al., 2000; Niccoli et al., 2002). In
one small, uncontrolled observational study, indomethacin
use was associated with an increase in serum potassium con-
centrations (Zimran et al., 1985). Another recent observa-
tional study, which controlled for confounders, reported a
higher risk of hyperkalemia in patients who were prescribed
selective COX-2 inhibitors compared to those who were
prescribed non-selective NSAIDs (Aljadhey et al., 2010).
The results of these studies need to be conﬁrmed in future
studies that involve patients from other geographical regions.
For many reasons, the response of patients in Saudi Arabia to
medications may be different than the responses of patients
who live in Western countries. For practitioners and policy
makers, local studies are needed to guide treatment choices,
the practice and any decisions that are made regarding the
safety of medications. However, no studies have examined
the effects of NSAIDs on serum potassium concentrations
in Saudi Arabia.
An adverse drug reaction (ADR) is deﬁned by the World
Health Organization as ‘‘an effect which is noxious and unin-
tended, and which occurs at doses used in man for prophy-
laxis, diagnosis, or therapy’’ (Jha et al., 1998). The studies
that are conducted before marketing a drug may not detect
all of the ADRs because of small sample sizes, the exclusion
of patients with comorbidities, and a short period of follow-
up. After marketing, these drugs will be used by a larger num-
ber of patients, and new ADRs may be reported to health
authorities. Next, pharmacovigilance and data mining are con-
ducted to detect safety signals. However, ADR reports are lim-
ited because of underreporting and incomplete information
about the concomitant medications and comorbidities of theinvolved patients. In addition, the absence of a control group
in pharmacovigilance testing makes it difﬁcult to attribute the
ADR to the drug, especially for ADRs with a high background
prevalence rate. Therefore, a pharmacoepidemiologic study is
needed that includes patients from clinical practice and that
compares the risk of ADR in these patients to the risk of pa-
tients in a control group after controlling for confounders.
These studies would also support the causal relationship be-
tween the ADR and the drug.
To conduct a pharmacoepidemiologic study in an efﬁcient
and time-sensitive manner, a computerized database is needed.
A computerized database can handle large sample sizes and is
relatively inexpensive to use (Strom and Carson, 1990; Garcı´a
Rodrı´guez and Pe´rez Gutthann, 1998). This database needs to
include administrative, prescription, and clinical components.
In Saudi Arabia, no such database is available to conduct
pharmacoepidemiological studies. Therefore, the objective of
the present study was to determine the feasibility of conducting
pharmacoepidemiological studies in Saudi Arabia using reﬁll
prescription data in a tertiary hospital to investigate the asso-
ciation between NSAIDs and increased serum potassium
concentrations.2. Method
2.1. Design and subjects
This retrospective cohort study included adult patients who re-
ceived their ﬁrst prescription for an NSAID from an outpa-
tient clinic at a tertiary hospital in Riyadh, Saudi Arabia.
We used a new user design to detect early-onset adverse effects
(Ray, 2003). The index date was deﬁned as the date of the ﬁrst
NSAID prescription between 2000 and 2010. The included pa-
tients did not have an active prescription for any NSAID dur-
ing the year preceding the starting index date. Non-selective
and selective NSAIDs were included in the study. The patients
who did not have their serum potassium concentrations tested
during the year before and the year after the index date were
excluded from the present study. The control group was a ran-
dom sample of patients from the same outpatient clinics who
were prescribed paracetamol. These users of paracetamol were
selected as the control group because patients with osteoarthri-
tis pain are usually prescribed either paracetamol or NSAIDs.
The present study was approved by the appropriate ethics
committee.
2.2. Endpoint
The studied outcome was a serum potassium concentration
>5 mEq/L. The ﬁrst potassium concentration determination
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on potassium homeostasis manifest within several days to a
week (Murray et al., 1997). In addition, physicians may change
the treatments based on observed increases in potassium levels.
2.3. Covariates
Based on those in the previous literature, included covariates
were age, sex, baseline serum potassium concentrations, and
baseline serum creatinine levels. Also, the use of medications
that were known to be associated with an increase in potas-
sium concentrations were included, including angiotensin-con-
verting enzyme inhibitors, angiotensin II antagonists, diuretics,
and potassium supplements. The use of calcium channel block-
ers, beta blockers, diuretics, antidiabetic medications, and stat-
ins was also controlled in the model.
2.4. Data analysis
The serum potassium concentration data were collected for
each patient for the years before and after the start date of
the ﬁrst prescription for an NSAID. The information on the
relevant confounders was collected at the baseline. The end
date of the follow-up was deﬁned as either one year after the
ﬁrst prescription or 30 days after the last dispensed prescrip-
tion, depending on which date was nearer to the completion
of the study.
The chi-squared test was used to analyze the categorical
variables, and the t-test was used to analyze the continuous
variables. The Statistical Package for the Social Sciences
(SPSS) software, version 17, was used for the analyses and
to calculate the odds ratio of the hyperkalemia risk in the
NSAID group compared to the control group after controlling
for the aforementioned covariates. The corresponding 95%
conﬁdence intervals were calculated, and P-values for the odds
ratios were calculated using the chi-squared distribution.
3. Results
A total of 184 patients were prescribed NSAIDs (n= 101) or
paracetamol (n= 83) and met the inclusion criteria. The spe-
ciﬁc NSAIDs that were prescribed to the patients were cele-
coxib, diclofenac, ibuprofen, and meloxicam (Table 1).
Compared to the control group, the patients who received
NSAIDs were more likely to be women, were less likely to
use angiotensin-converting enzyme inhibitors, and were more
likely to have lower baseline serum creatinine concentrations.
The other baseline characteristics were similar between the pa-







Total 101(100%)(Table 2). The mean age of the NSAID users was 58 ± 13
years, and 66% were women. The mean potassium concentra-
tions (SD) before the index date were 4.4 ± 0.44 mEq/L and
4.4 ± 0.47 mEq/L for the NSAID and paracetamol groups,
respectively.
After controlling for age, sex, baseline serum creatinine le-
vel, baseline serum potassium level, and the use of medica-
tions, there was no increase in the risk of hyperkalemia in
the patients who were prescribed NSAIDs compared to those
who were prescribed paracetamol (odds ratio, 1.1 95% conﬁ-
dence interval, 0.17–6.7, P= 0.95).4. Discussion
The present study is the ﬁrst observational study in Saudi Ara-
bia to explore the association between NSAIDs and increased
serum potassium concentrations using pharmacy prescription
data. The risk of hyperkalemia did not increase in the NSAID
users compared to the control group. The lack of difference be-
tween the groups was mainly due to the small sample size;
given the small sample size, the present study was not sufﬁ-
ciently powered to detect small differences between the groups.
Another limitation of the current study was that the patients
were collected from a single hospital, and thus, the results
may not be generalizable. Therefore, the present study should
be replicated in other settings and with greater numbers of
patients.
In Saudi Arabia, it is feasible to use clinical information for
pharmacoepidemiologic studies. However, collecting the data
manually is demanding and time consuming. For time and efﬁ-
ciency, a computerized clinical database is needed to conduct
pharmacoepidemiologic studies (Strom and Carson, 1990;
Garcı´a Rodrı´guez and Pe´rez Gutthann, 1998). Such databases
include other clinical comorbidities to control for when study-
ing the adverse effects of medications. The Regenstrief Medical
Record System (RMRS) in the United States and the General
Practice Research Database (GPRD) in the United Kingdom
are examples of computerized clinical databases (Garcı´a Rod-
rı´guez and Pe´rez Gutthann, 1998; McDonald et al., 1999; Mur-
ray et al., 2003). The RMRS captures and stores patient data
from outpatient medical practices, emergency departments,
and hospitals at the Indiana University Medical Center and
from 30 practices throughout the city of Indianapolis. Among
the data that have been captured by the RMRS are pharmacy
prescriptions, laboratory data, and other clinical data in a
coded and readily retrievable form (McDonald et al., 1999;
Murray et al., 2003). In the United Kingdom, the GPRD
has outpatient and inpatient clinical information and includes
more than three million patients (Garcı´a Rodrı´guez and Pe´rez
Gutthann, 1998).
In the last decade, efforts have been made in Saudi Arabia
to implement information technology in the healthcare system
and to build an electronic medical ﬁling system. These comput-
erized healthcare data can be utilized to study the efﬁcacy and
safety of medications to improve the health of the public. The
model for building a clinical database in Saudi Arabia needs to
be selected carefully by stakeholders. The database must fulﬁll
the requirements that are needed to conduct research in the
areas of efﬁcacy, safety, and drug utilization. In addition, it
is better to build this database internally so that it can be ad-
justed based on changes in the healthcare system in Saudi
Table 2 Comparison of baseline characteristics between patients prescribed nonsteroidal anti-inﬂammatory drugs and patients
prescribed paracetamol.
Variable NSAIDs N (%) (n= 101) Paracetamol N (%) (n= 83) P valuec





Angiotensin-converting enzyme inhibitor (ACE-I) 46(46%) 50(60%) 0.04
Calcium channel blocker (CC) 47(47%) 43(52%) 0.47
Beta blocker 44(44%) 45(54%) 0.15
Angiotensin receptor blocker (ARB) 9(9%) 11(13%) 0.34
Diuretics 12(12%) 11(13%) 0.77
Diabetic drugs 24(24%) 19(23%) 0.89
Statin 36(36%) 33(40%) 0.56
Nitrates 7(7%) 13(16%) 0.05
Cardiovascular drugs 6(6%) 9(11%) 0.22
Others 21(21%) 19(23%) 0.75
Baseline serum potassium (mEq/L)a 4.4(±0.44) 4.4(±0.47) 0.69
Baseline serum creatinine (lmol/L)a 97.3(±119.4) 133.1(±191.7) 0.03
a Mean (±SD).
b Because of rounding it may not add to 100%.
c P-value of t-tests for continuous variables and chi-square tests for categorical variables.
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need to be addressed regarding sharing patients’ personal data.
One option to protect patient information is to build a net-
work of databases that are similar to the Sentinel System in
the United States, in which hospitals share only the results
of the data analysis and keep the patient’s health data conﬁ-
dential (Behrman et al., 2011).
In summary, the present, small feasibility study did not re-
veal an increase in the risk of hyperkalemia associated with
NSAIDs compared to paracetamol. The present study was
exploratory and included a small number of patients; there-
fore, it may not be sufﬁciently powered to detect small differ-
ences between groups. Future studies with larger sample sizes
are needed to investigate the association between NSAIDs
and hyperkalemia.
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